DIA China 2026

The Leading Australian CRO for Early Phase Clinical Trials

Recognized as Australia’s leading early phase CRO, Avance Clinical supports biotechs with fast, globally aligned early phase development pathways. Australia’s clinical research environment offers several distinct advantages, including

• Fast ethics approvals, with first-in-patient possible in as little as five to six weeks
• No IND requirement, reducing regulatory burden
• Up to 43.5% R&D tax rebate on eligible clinical trial costs
• High-quality data accepted by major global regulators including TGA, FDA, EMA, and MHRA

Avance Clinical is the industry leader in leveraging these advantages to help biotechs reach proof-of-concept sooner, manage costs effectively, and transition smoothly into global later-phase programs.